CLX

Business profile & competitive position

The Clorox Company operates inside the Consumer Defensive sector, specifically the Household & Personal Products industry. Its portfolio centers on everyday consumables: disinfecting bleach, wipes, cleaners, trash bags, cat litter, water filtration, and personal-care/hygiene brands. These products are recurring purchases, which normally produces stable top-line visibility and some pricing power.

Recent numbers paint a mixed picture of that positioning. The company's net margin sits at 8.7%, a level that suggests it is not merely a commodity producer but a branded staples operator able to earn a profit after all costs. The stock's beta of 0.53 reinforces that defensive profile: CLX has historically moved roughly half as much as the overall market during broad swings. However, return on equity is reported at -1,893.5%, an extreme negative figure that overwhelms the margin story. That reading is not consistent with ordinary operating losses while earning an 8.7% net margin; it typically signals a very small or negative shareholders' equity base, possibly from large buybacks, past impairments, or leverage. Because the data do not specify the balance-sheet driver, the ROE cannot be interpreted as a clean measure of competitive advantage. What the margin and beta figures do support is a business with relatively predictable demand; what the ROE demands is a separate look at how the company is capitalized.

Financial posture

Clorox currently carries a market capitalization of $12.7 billion, trades at a trailing P/E of 21.9, and posts an 8.7% net margin. At $105.34, it also sits above its 50-day EMA of $98.16, with an RSI of 62.7 suggesting neither oversold nor heavily overbought territory on the daily chart.

The valuation math is straightforward: a P/E near 22 is more expensive than deep-value names but sits within the range investors routinely assign to large, dividend-paying household brands with low beta. The 8.7% net margin supports that premium relative to a name with no pricing power. The biggest caveat in the financial posture is the same extreme ROE. A negative ROE of -1,893.5% cannot be dismissed as a rounding error; it implies equity is tiny or negative on the balance sheet, so any earnings number mechanically produces an outsized percentage. Until that line item is reconciled, the standard P/E and margin metrics tell only part of the story. The combination of low beta and this capital-structure anomaly makes CLX look defensive in its operations but not necessarily conservative in its financing.

Macro & geopolitical exposure

Because Clorox is classified as Household & Personal Products within Consumer Defensive, its exposures are those of a global branded staples manufacturer. Product costs are tied to petrochemicals, resins, and pulp-based packaging, while distribution costs move with freight rates, diesel prices, and labor. Inflation in those inputs directly affects gross margin unless the company can raise prices or cut costs fast enough to offset them.

Beyond commodity and labor inflation, the industry faces private-label substitution when shoppers trade down, retailer concentration that limits pricing flexibility, and regulatory risk from the EPA on disinfectant claims, FTC labeling requirements, and product-recall exposure. Currency matters for any international revenue, as do tariffs or supply-chain disruptions that affect imported raw materials or finished goods. The recent earnings call explicitly flagged inflation, which fits the sector narrative: a consumer-staples company can see steady unit demand while still fighting margin pressure from inputs. The business is not cyclical in the same way as industrials or discretionary names, but it is not immune to macro or policy-driven cost shocks.

Recent developments

The most recent news cluster came immediately after Clorox's fiscal Q4 report. On August 4, 2026, Zacks published two stories: one noting that Clorox Q4 Earnings & Sales Top Estimates as GOJO Supports Sales, and another headlined CLX Q4 Earnings Call Flags Inflation as Share Recovery Builds. The same day, Benzinga reported that These Analysts Boost Their Forecasts On Clorox Following Better-Than-Expected Q4 Results. A day later, on August 6, 2026, Zacks ran a comparative piece, NWL vs. CLX: Which Stock Is the Better Value Option?

These headlines carry a few clear takeaways. First, the GOJO business—acquired to expand the professional cleaning and hand-hygiene footprint—appears to be contributing to top-line growth, which is why it is highlighted as a sales driver. Second, while the quarter beat estimates, management was not declaring victory; inflation remains a live topic on the conference call. Third, the improved quarter was enough for sell-side analysts to raise their forecasts, a dynamic captured by Benzinga's coverage. Finally, the value comparison with Newell Brands places CLX in the broader staples peer conversation, framing the stock as a valuation alternative rather than an isolated story.

Earnings behavior & post-earnings drift

Clorox has delivered a strong estimate-beating record over the last eight reported quarters: 6 beats out of 8, or a 75% beat rate, with an average earnings surprise of 9.4%. The average five-day return in the sessions after those reports is +0.87%, classified as an upward post-earnings drift. That average masks a lot of noise.

The last four quarters illustrate the point. On August 3, 2026, CLX reported EPS of $1.66 against a $1.64 estimate, a modest 1.2% beat; the stock rose 6.52% the next day and 6.42% over the following five days. The prior quarter, April 30, 2026, was a larger beat, with actual EPS of $1.64 versus $1.55 expected, a 5.8% surprise, yet the stock fell 9.67% the next day and 4.49% over five days. On February 3, 2026, CLX missed by 2.8%, posting $1.39 against $1.43; the market reacted positively anyway, up 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter beat by 3.9%, with $0.85 versus $0.818, but the stock gained only 1.17% the next day and slid 4.08% over the next week.

The takeaway is that beats and misses alone do not determine the price reaction. Full-year guidance, margin commentary, and the market's real expectation all feed into the post-earnings move. The next report is scheduled for November 3, 2026, after the close, with the current consensus EPS estimate at $1.07.

For a deeper dive into how the sell side now views Clorox—rating distribution, estimate revisions, and the full institutional verdict—the consensus analyst page is the next logical stop.